SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S23744.
  • 2
    Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 3506.
  • 3
    Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91: 30913.
  • 4
    Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alpha. Br J Ophthalmol 1995; 79: 1502.
  • 5
    Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 11713.
  • 6
    Saito H, Ebinuma H, Nagata H, et al. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001; 21: 1927.
  • 7
    Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alpha-2b therapy. Am J Ophthalmol 2001; 131: 7827.
  • 8
    Chambers RB, Downie A, Foote B, et al. Interferon alpha-associated retinopathy. J Am Osteopathol Assoc 1997; 97: 435.
  • 9
    Kadayifcilar S, Kart H, Gursoy M, et al. Ocular complication with high-dose interferon alpha in chronic active hepatitis. Eye 1999; 13: 2416.
  • 10
    Tokai R, Ikeda T, Miyaura T, et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol 2001; 119: 10779.
  • 11
    Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon-associated retinopathy. Br J Ophthalmol 1998; 82: 3235.
  • 12
    Schulman JA, Liang C, Kooragayala LM, et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110: 43742.
  • 13
    Tu KL, Bowyer J, Schofield K, et al. Severe interferon associated retinopathy. Br J Ophthalmol 2003; 87: 2478.
  • 14
    Savant V, Gallow T. Interferon-associated retinopathy. Eye 2002; 17: 5346.
  • 15
    Rubio JE Jr, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina 2003; 23: 5468.
  • 16
    Norcia F, Di Maria A, Prandini F, et al. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999; 213: 33940.
  • 17
    Sugano S, Suzuki T, Watanabe T, et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93: 24414.
    Direct Link:
  • 18
    Brouty-Boye D, Zetter B. Inhibition of cell motility by interferon. Science 1980; 108: 5168.
  • 19
    Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma interferon. J Cell Biol 1987; 104: 68996.
  • 20
    Sidky Y, Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 515561.
  • 21
    Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100: 914.
  • 22
    Purvin VA. Anterior ischaemic optic neuropathy secondary to interferon alpha. Arch Ophthalmol 1995; 133: 10414.
  • 23
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 24
    Kuchenbecker J, Pump-Schmidt C, Olbright S, et al. Electrophysiological examination of breast cancer patients with tamoxifen retinopathy. Ophthalmologe 2001; 98: 815.
  • 25
    Lazzaroni F, Scorolli L, Pizzoleo CF, et al. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol 1998; 236: 66973.
  • 26
    Jiang C, Hansen RM, Gee BE, et al. Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol 199899; 96: 33345.
  • 27
    Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999; 353: 375.
  • 28
    Sandberg MA, Rose JB, Bernson EL. Cone and rod function in vitamin A deficiency with chronic alcoholism and in retinitis pigmentosa. Am J Ophthalmol 1977; 84: 65865.
  • 29
    Scholl HPN, Zrenner E. Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 2000; 45: 2947.
  • 30
    Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequency complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27: 14217.
  • 31
    McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 16904.
  • 32
    Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 2001; 102: 6372.
  • 33
    Harding GF, Wild JM, Robertson KA, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000; 41: 142031.
  • 34
    Penrose PJ, Tzekov RT, Sutter EE, et al. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 2003; 23: 50312.
  • 35
    Marmor MF, Hood DC, Keating D, et al. Guidelines for basic multifocal electroretinography. Doc Ophthalmol 2003; 106: 10515.
  • 36
    Sutter EE, Tran D. The field topography of ERG components in man: I. The photopic luminance response. Vis Res 1992; 32: 43346.
  • 37
    Sutter EE. Imaging visual function with the multifocal m-sequence technique. Vis Res 2001; 41: 124155.
  • 38
    Brown GC. Retinal arterial obstructive disease. In: Schachat, AP, Murphy, RB, Ryan, SJ, eds. Retina, Vol. 2, Medical Retina. St Louis, Missouri, USA: Mosby-Year Book, 1994: 136177.
  • 39
    Brown GC, Brown MM, Hiller T, et al. Cotton wool spots. Retina 1985; 5: 20614.
  • 40
    Hood DC. Assessing retinal function with the multifocal technique. Prog Ret Eye Res 2000; 19: 60746.
  • 41
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 42
    Zegans ME, Anninger W, Chapman C, et al. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2001; 13: 4237.
  • 43
    Keeling PW, O'Day J, Ruse W, et al. Zinc deficiency and photoreceptor dysfunction in chronic liver disease. Clin Sci (Lond) 1982; 62: 10911.
  • 44
    Parks SW, Sandinha T, Purdie A, et al. Do rods have a significant influence on the photopic multifocal ERG response? An interesting case. Invest Ophthalmol Vis Sci 2004; 45: S4235.
  • 45
    Forton DM, Thomas HC, Murphy C, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 4339.
  • 46
    Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 816.